Compare Global E Online Ltd (GLBE) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Natera Inc. Common Stock — how do they compare? Global E Online Ltd trades at $38.28 (market cap $6.55B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 8.7× Global E Online Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Global E Online Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Natera Inc. Common Stock for 0 Days on average.
| GLBE | NTRA | |
|---|---|---|
Market Cap | $6.55B | $57.03B |
Volume | 1,171,020 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $425.64 |
52-Week Low | $27.54 | $179.42 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $6.05B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $39.00, down 0.05% with a bearish technical signal. The company shows strong fundamentals with Q2 2026 earnings beating expectations and revenue growth accelerating to 39% year-over-year. Analyst sentiment remains overwhelmingly positive with 93% buy ratings and a $48.86 consensus price target representing 25% upside potential. Recent executive appointments and strong Q2 results have driven positive momentum, though insider selling activity warrants monitoring.
The outlook remains favorable with projected revenue growth to $1.1B in 2026 and expanding profit margins. Key risks include competitive pressures in e-commerce enablement and potential market volatility. The stock's current valuation at 44.32 P/E reflects growth expectations, with technical resistance at $40 needing to be overcome for further upside.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
